Covered without prior authorization (high confidence)
Documentation Required
Clinical evidence supporting diagnosis (e.g., laboratory or diagnostic test results, such as pathogen identification by appropriate testing) and medical records showing clinical severity and rationale for inhaled ribavirin therapy.
Records demonstrating treatment regimen and administration details as applicable (the CPB cites recommended dosing regimen: 20 mg/mL Virazole in SPAG-2 unit with continuous aerosol administration 12-18 hours/day for 3-7 days as recommended dosing information from Virazole prescribing information).
No explicit 'Documentation Requirements' section or specific documentation checklist is provided in this CPB.
Implied/expected documentation (not explicitly required by policy text): documentation supporting the covered diagnosis (e.g., clinical diagnosis of RSV, viral hemorrhagic fever, Rift Valley fever, Hantaan infection) and that patient meets the described population (e.g., immunosuppressed or high-risk child/adult; hospitalized infant/young child with severe LRTI due to RSV).
Key Coverage Criteria
Ribavirin (Virazole) inhalation medically necessary for the treatment of: Respiratory syncytial virus (RSV) infection in immunosuppressed and high risk children and adults;
Ribavirin (Virazole) inhalation medically necessary for the treatment of: Viral hemorrhagic fever (Crimean-Congo, Ebola, Lassa, and Marburg);
Ribavirin (Virazole) inhalation medically necessary for the treatment of: Rift valley fever and Hantaan, a hanta virus.
FDA-Approved indication: Virazole (ribavirin for inhalation solution, USP) is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to RSV.